Mineralys Therapeutics (MLYS) Q2 FY26 earnings call

Mineralys Therapeutics is in a strong financial position as it approaches the PDUFA date for lorundrostat, having secured substantial capital through an equity offering and term loan, alongside a strategic royalty repurchase. The company is actively building its commercial infrastructure and engaging with payers, while continuing to generate supportive clinical data for lorundrostat's potential best-in-class profile. Management expressed confidence in its launch readiness and the market opportunity for this new class of antihypertensive therapy.